Sangamo Therapeutics Profit Margin

Sangamo Therapeutics (SGMO) currently reports a profit margin of -356.89% as of March 2026. That compares with -124.61% in the prior-year period — down 186.4% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Sangamo Therapeutics's profit margin history and peer comparisons.

Sangamo Therapeutics's profit margin decreased from -124.61% to -356.89% — a 186.4% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sangamo Therapeutics's profit margin of -356.89% is lower than the Healthcare sector average of 21.34%. That is roughly 1772.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Sangamo Therapeutics's current -356.89% should be judged against Healthcare norms (sector average: 21.34%) and against SGMO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -356.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Sangamo Therapeutics, and consider following SGMO for alerts when major investors trade the stock.